CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Health

Other Health

IMULDOSA

More Like This

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®

PR Newswire associated0

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)

European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara® (ustekinumab), for the treatment of multiple chronic inflammatory diseases

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

PR Newswire associated0

Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion from the EMA

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars